Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine

NEXT STORY
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma
PREV STORY
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Silo Wellness Appoints Phytomedicine Business Leader as Board Member

author_avatar
NASDAQ Market News

Arno Therapeutics Reports First Quarter 2016 Financial and Business Update

FLEMINGTON, N.J., May 16, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical ...

author_avatar
NASDAQ Market News

Nufactor’s California Pharmacy Recognized as First Pharmacy to Achieve Immunoglobulin National Society’s (IgNS) Ig Certified Pharmacist (IgCP®) Credentialing

author_avatar
NASDAQ Market News